TABLE 2.
Changes within the R5 phenotype over time
| Patienta | Patient codeb | No. of R5 isolates | Time between first and last R5 isolate (mo) | CD4 cell count (106 cells/liter) at the time of isolation
|
Phenotype of R5 isolatec
|
Antiretroviral therapy at time of isolatione
|
|||
|---|---|---|---|---|---|---|---|---|---|
| First | Last | First | Last | First | Last | ||||
| R5 nonswitch | |||||||||
| 292 | I | 2 | 41 | 140 | 90 | Narrow | Broad(2) | AZT | AZT + ddI |
| 435 | 10 | 54 | 730 | 462 | Narrow | Narrow | |||
| 451 | J | 2 | 31 | 220 | 20 | Broad(1) | Broad(1) | AZT | ddI |
| 1047 | 14 | 99 | 630d | 360 | Broad(1) | Broad(1) | |||
| 1276 | 9 | 80 | 320 | 40 | Narrow | Broad(2) | ddI | ||
| 1838 | 4 | 63 | 455 | 290 | Narrow | Broad(1) | |||
| 1703 | F | 2 | 27 | 310 | 190 | Broad(1) | Narrow | AZT | AZT |
| 2010 | G | 2 | 35 | 260 | 5 | Broad(2) | Broad(3) | AZT | ddI |
| 2061 | L | 2 | 44 | 220 | 13 | Broad(3) | Broad(3) | ||
| 2146 | M | 2 | 74 | 750 | 20 | Broad(2) | Broad(3) | AZT | |
| 2216 | H | 2 | 33 | 290 | 6 | Broad(2) | Broad(3) | ||
| 2245 | N | 3 | 64 | 310 | 280 | Broad(2) | Broad(1) | ||
| 3408 | O | 3 | 77 | 270 | 140 | Broad(1) | Broad(2) | HAART | |
| 4021 | Q | 3 | 58 | 240 | 220 | Broad(1) | Broad(1) | AZT | HAART |
| 4468 | R | 2 | 18 | 200 | 9 | Broad(1) | Broad(3) | AZT | |
| R5 switch | |||||||||
| 958 | 5 | 26 | 300d | 30 | Narrow | Broad(2) | AZT | ||
| 965 | 11 | 41 | 310 | 360d | Narrow | Broad(2) | AZT | ||
| 1023 | 4 | 36 | 500 | 500 | Broad(2) | Broad(3) | |||
| 1679 | 23 | 26 | 230 | 81 | Broad(2) | Broad(3) | AZT | ||
| 1991 | 13 | 39 | 260 | 160 | Broad(2) | Broad(3) | AZT | ||
| 2112 | 6 | 42 | 340d | 338 | Broad(1) | Broad(3) | AZT | ||
| 2239 | 2 | 20 | 730 | 410 | Broad(1) | Broad(1) | |||
| 2242 | 18 | 49 | 260 | 119 | Broad(2) | Broad(3) | AZT | ||
| 2282 | 7 | 34 | 350 | 163 | Broad(3) | Broad(2) | AZT | ||
| 2289 | 10 | 48 | 490d | 250 | Broad(2) | Broad(3) | AZT | ||
| 3382 | 3 | 38 | 150 | 160 | Broad(2) | Broad(1) | |||
a
R5 nonswitch, R5 phenotype was maintained throughout the study period; R5 switch, later acquisition of CXCR4-using virus.
b
Patient code used by Jansson and coauthors (29).
c
Narrow, virus using wild-type CCR5 but no chimeric receptor; Broad(1) to Broad(3), virus able to use one to three chimeric receptors in addition to CCR5.
d
CD4+-T-cell count was not available at the exact time point; the closest previous value is used.
e
AZT, zidovudine; ddI, didanosine; HAART, highly active antiretroviral therapy.